• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Jingrong,LIANG Bingyi,PENG Wei,GAO Yongjian,LIN Bishan,ZENG Shan,TANG Chunhua,CHEN Jinxia,SU Weiwei.Study on the potential active components and molecular mechanism of Danggui Liuhuang Decoction in the treatment of ulcerative colitis based on bioinformatics and molecular docking technology[J].Journal Of Pharmaceutical Research,2022,41(9):561-569[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2193times   Download 2818次 QR Code for this article
Scan with your phone!
基于生物信息学和分子对接技术研究当归六黄汤治疗溃疡性结肠炎潜在活性成分及分子机制
李静荣1,梁冰宜1,彭维1,高永坚2,林碧珊2,曾杉2,汤春花2,陈锦霞2,苏薇薇1
Font:Larger+|Default|Smaller-
(1.中山大学生命科学学院,广东省中药上市后质量与药效再评价工程技术研究中心,广东 广州 510275;2.国药集团广东环球制药有限公司,广东 佛山 528000)
摘要:
目的 采用生物信息学和分子对接技术,探讨当归六黄汤(DGLHD)治疗溃疡性结肠炎(UC)的作用机制。方法 采用公共数据库(TCMSP、DrugBank和UniProt)寻找当归六黄汤的有效活性成分和相应的靶基因,构建DGLHD活性成分-靶蛋白相互作用网络。基于DisGeNET数据库、Genecards数据库和DrugBank数据库检索溃疡性结肠炎相关基因,获取当归六黄汤与溃疡性结肠炎的交集靶点基因。利用STRING在线数据库进行蛋白质-蛋白质相互作用关系(PPI)分析,获取核心靶点基因。采用Metascape在线数据库进行基因本体(GO)功能注释及KEGG通路富集。通过DiscoveryStudio 2016进行分子对接,确定药物活性成分与核心靶标相互作用的分子基础。结果 共筛选出82种活性化合物和132个交集靶基因。核心靶点基因涉及信号传导与转录激活因子3(STAT3)、TP53、AKT1、MAPK1、JUN和血管内皮生长因子A(VEGFA);通路富集主要为“肿瘤信号通路”、“糖尿病并发症中晚期糖基化终产物及其受体(AGE-RAGE)信号通路”“内分泌抵抗”、“NF-κB信号通路”、“Th17细胞分化”。分子对接结果表明,当归六黄汤核心活性成分可以通过氢键等相互作用与核心靶基因形成稳定的对接模式。结论 基于生物信息学和分子对接技术,筛选出当归六黄汤治疗溃疡性结肠炎的活性成分、核心靶点及主要信号通路,为当归六黄汤治疗溃疡性结肠炎提供了新的理论基础。
关键词:  当归六黄汤  溃疡性结肠炎  网络药理学  分子对接
DOI:10.13506/j.cnki.jpr.2022.09.001
基金项目:佛山市重点领域科技攻关项目(No.2120001007987)
Publication Date:September 25, 2022
Study on the potential active components and molecular mechanism of Danggui Liuhuang Decoction in the treatment of ulcerative colitis based on bioinformatics and molecular docking technology
LI Jingrong1,LIANG Bingyi1,PENG Wei1,GAO Yongjian2,LIN Bishan2,ZENG Shan2,TANG Chunhua2,CHEN Jinxia2,SU Weiwei1
(1.Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275,China;2.Sinopharm Group Guangdong Medi-Word Pharmaceutical Co.,Ltd.,Foshan 528305,China)
Abstract:
Objective To explore the molecular basis and mechanism of Danggui Liuhuang Decoction (DGLHD) in the treatment of ulcerative colitis (UC) by bioinformatics technology and molecular docking technology.Methods Effective active ingredients and corresponding targets of DGLHD were determined from the Public databases including TCMSP, DrugBank, and UniProt, and the drug ingredient-target network was constructed. The disease targets related to UC were obtained based on the GeneCards, DisGeNET and DrugBank databases. Then, the drug ingredient and disease targets were intersected to construct a protein-protein interaction network through the STRING database. The Metascape database was used for the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) pathway enrichment analyses of the core targets to explain the biological functions and signal pathways of the core proteins. Finally, molecular docking is performed through Discovery Studio 2016, so as to verify the binding ability between the active components of the drug and the core target protein.Results DGLHD has been screened out of 82 potentially effective active compounds and 132 intersected genes. Through topological analysis of PPI network, core targets was found including STAT3,TP53,AKT1,MAPK1,JUN and VEGFA. KEGG enrichment analysis showed that genes were particularly enriched in pathways in cancer, AGE-RAGE signaling pathway in diabetic complications, Hepatitis B, endocrine resistance, IL-17 signaling pathway, NF-κB signaling pathway and other pathways. Finally, the molecular docking verification demonstrates that some active components of the drug have good molecular docking and binding ability with the core target protein.Conclusion Based on the research foundation of bioinformatics and molecular docking technology, the active components and core target molecules of DGLHD for the treatment of UC are screened out, and the potential mechanism of DGLHD inhibiting UC is deeply explored. The results provide theoretical basis for DGLHD in the treatment of UC.
Key words:  Danggui Liuhuang Decoction  Ulcerative Colitis  Bioinformatics  Molecular Docking
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.